Claims
- 1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
(a) a polynucleotide encoding amino acids from about 1 to about 529 of the amino acid sequence contained in SEQ ID NO:2; (b) a polynucleotide encoding amino acids from about 2 to about 259 of the amino acid sequence contained in SEQ ID NO:2; (c) the polynucleotide complement of the polynucleotide of (a) or (b); and (d) a polynucleotide at least 90% identical to the polynucleotide of (a), (b) or (c).
- 2. An isolated nucleic acid molecule comprising about 2 to about 2468 contiguous nucleotides from the nucleic acid sequence contained in SEQ ID NO:1.
- 3. An isolated nucleic acid molecule comprising about 50 to about 200 contiguous nucleotides from the nucleic acid sequence identified in SEQ ID NO:1.
- 4. An isolated nucleic acid molecule comprising about 2 to about 1589 contiguous nucleotides of the nucleic acid sequence contained in SEQ ID NO:1.
- 5. An isolated nucleic acid molecule comprising about 10 to about 300 contiguous nucleotides from the nucleic acid sequence contained in SEQ ID NO:1.
- 6. An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for at least one conservative amino acid substitution, said polynucleotide has an amino acid sequence selected from the group consisting of:
(a) amino acids from about 1 to about 529 of the amino acid sequence in SEQ ID NO:2; and (b) amino acids from about 2 to about 529 of the amino acid sequence in SEQ ID NO:2.
- 7. The isolated nucleic acid molecule of claim 1, which is DNA.
- 8. A method of making a recombinant vector comprising inserting a nucleic acid molecule of claim 1 into a vector in operable linkage to a promoter.
- 9. A recombinant vector produced by the method of claim 8.
- 10. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 9 into a host cell.
- 11. A recombinant host cell produced by the method of claim 10.
- 12. A recombinant method of producing a polypeptide, comprising culturing the recombinant host cell of claim 11 under conditions such that said polypeptide is expressed and recovering said polypeptide.
- 13. An isolated polypeptide comprising amino acids at least 95% identical to amino acids selected from the group consisting of:
(a) amino acids from about 1 to about 529 of the amino acid sequence contained in SEQ ID NO:2; and (b) amino acids from about 2 to about 529 of the open amino acid sequence contained in SEQ ID NO:2.
- 14. An isolated polypeptide wherein, except for at least one conservation amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
(a) amino acids from about 1 to about 529 of the amino acid sequence in SEQ ID NO:2; and (b) amino acids from about 2 to about 529 of the amino acid sequence in SEQ ID NO:2.
- 15. An isolated polypeptide comprising amino acids selected from the group consisting of:
(a) amino acids from about 1 to about 529 of the amino acid sequence in SEQ ID NO:2; and (b) amino acids from about 2 to about 529 of the amino acid sequence in SEQ ID NO:2.
- 16. An epitope-bearing portion of the polynucleotide identified in SEQ ID NO:2.
- 17. The epitope-bearing portion of claim 16, which comprises about 5 to about 30 contiguous amino acids of the protein in SEQ ID NO:2.
- 18. The epitope-bearing portion of claim 17, which comprises about 10 to about 15 contiguous amino acids of the protein in SEQ ID NO:2.
- 19. An isolated antibody that binds specifically to the polypeptide of claim 15.
- 20. A monoclonal antibody according to claim 19.
- 21. A method of modulating apoptosis or proliferation of a cancer cell, comprising regulating expression of BRCC-3 in said mammalian cell.
- 22. The method of claim 21, wherein said mammalian cell is transformed with a vector encoding an antisense oligonucleotide corresponding to the BRCC-3 sequence in SEQ ID NO:1 or to a fragment thereof.
- 23. An antisense oligonucleotide that inhibits the expression of BRCC-3 in a mammalian cell.
- 24. The antisense oligonucleotide of claim 23 which is contained in a liposomal formulation.
- 25. A method of treating cancer characterized by BRCC-3 overexpression by administration of an antisense oligonucleotide or ribozyme that modulates BRCC-3 expression.
- 26. A method of treating cancer characterized by BRCC-3 overexpression comprising administering an antibody that specifically binds BRCC-3.
- 27. A method of detecting cancer characterized by BRCC-3 overexpression or BRCC-3 underexpression comprising detecting the levels of BRCC-3 expression and correlating said level of expression to the presence or absence of cancer.
- 28. The method of claim 27 which is effected by using a cDNA that hybridizes BRCC-3 and mRNA.
- 29. The method of claim 27 which is effected by using an antibody that specifically binds BRCC-3.
- 30. A method of modulating cancer cell proliferation and/or metastasis in a cancer patient comprising administering a ribozyme or antisense oligonucleotide that modulates BRCC-3 expression.
- 31. The method of claim 30, wherein said cancer is breast cancer or lung cancer.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority to Provisional Application Serial No. 60/281,785, filed Apr. 6, 2001, which is incorporated by reference in its entirety herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60281785 |
Apr 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US02/10855 |
Apr 2002 |
US |
Child |
10679561 |
Oct 2003 |
US |